DSIP vs Teriparatide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
DSIP
Delta Sleep-Inducing Peptide is a neuropeptide that promotes delta wave sleep, the deepest and most restorative phase of the sleep cycle.
Full details →Teriparatide
Teriparatide (Forteo) is recombinant human parathyroid hormone (1-34), FDA-approved for osteoporosis treatment. It's unique among osteoporosis drugs in that it stimulates new bone formation.
Full details →Side-by-Side Comparison
| Aspect | DSIP | Teriparatide |
|---|---|---|
| Mechanism | Modulates sleep-wake cycles by affecting sleep spindles and delta rhythms. May also influence stress hormones and have analgesic properties. | Intermittent PTH exposure paradoxically stimulates osteoblasts more than osteoclasts, resulting in net bone formation. Continuous exposure would cause bone loss, but pulsatile dosing builds bone. |
| Typical Dosage | Typical dosing: 100-300mcg administered 30 minutes before sleep. Some protocols use it cyclically. | 20mcg subcutaneously once daily. Maximum treatment duration of 2 years due to theoretical osteosarcoma risk from rat studies. |
| Administration | Subcutaneous or intramuscular injection before bedtime. Some users report better results with cyclical use. | Subcutaneous injection in thigh or abdomen once daily. Delivered via multi-dose pen. Should sit or lie down after injection due to orthostatic hypotension risk. |
| Side Effects | May cause grogginess upon waking, vivid dreams, or temporary headaches. | Orthostatic hypotension, leg cramps, nausea, dizziness, headache, and injection site reactions. Transient hypercalcemia possible. |
| Best For |
What They Have in Common
Both DSIP and Teriparatide are commonly used for: